Vitamin D Research

back to research menu

Melanoma

• Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25‑hydroxyvitamin D deficiency in solid organ‑transplant recipients, xeroderma pigmentosum, and other risk groups?J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):664–7. Epub 2007 Jan 3.
• An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking.Int J Cancer. 2007 Mar 1;120(5):1123–8.
• A meta‑analysis of second cancers after a diagnosis of nonmelanoma skin cancer: Additional evidence that solar ultraviolet‑B irradiance reduces the risk of internal cancers.J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):668–74. Epub 2007 Jan 8.
• Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism.Br J Dermatol. 2007 Feb;156(2):277–82.
• Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma.J Invest Dermatol. 2007 Feb;127(2):276–80. Epub 2006 Sep 21.
• Vitamin D—an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience.Recent Results Cancer Res. 2007;174:197–204. Review.
• Solar ultraviolet‑B exposure and cancer incidence and mortality in the United States, 1993–2002.BMC Cancer. 2006 Nov 10;6:264.
• Does sunlight have a beneficial influence on certain cancers?Prog Biophys Mol Biol. 2006 Sep;92(1):132–9. Epub 2006 Feb 28. Review.
• Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25‑dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro.Anticancer Res. 2006 Jul–Aug;26(4A):2707–16.
• 1,25‑Dihydroxyvitamin D(3) inhibits tumor necrosis factor‑alpha‑induced adhesion molecule expression in endothelial cells.Cell Biol Int. 2006 Mar 17;
• The Molecular Basis of Vitamin D Receptor and beta‑Catenin Crossregulation.Mol Cell. 2006 Mar 17;21(6):799–809.
• Variation in incidence and fatality of melanoma by season of diagnosis in new South Wales, Australia.Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):524–6.
• Cutaneous melanoma and intervention strategies to reduce tumor‑related mortality: what we know, what we don't know, and what we think we know that isn't so.Dermatol Ther. 2006 Jan–Feb;19(1):50–69. Review.
• Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers.Mutat Res. 2005 Apr 1;571(1–2):207–19. Epub 2005 Jan 28.
• Seasonal variation in the diagnosis of cutaneous melanoma and non‑cutaneous malignancies: an Italian population‑based study.Melanoma Res. 2005 Feb;15(1):69–72.
• Sun exposure and mortality from melanoma.J Natl Cancer Inst. 2005 Feb 2;97(3):195–9.
• Sunlight and reduced risk of cancer: is the real story vitamin D?J Natl Cancer Inst. 2005 Feb 2;97(3):161–3.
• Seasonal variation in the occurrence of cutaneous melanoma in Europe: influence of latitude. An analysis using the eurocare group of registries.Eur J Cancer. 2005 Jan;41(1):126–32.
• Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up‑regulated in myeloid cells by 1,25‑dihydroxyvitamin D3FASEB. 2005;19:1067–1077.
• Seasonal variations in the diagnosis of cutaneous melanoma.J Am Acad Dermatol. 2004 May;50(5):679–82.
• Differential biological effects of 1,25‑dihydroxyVitamin D3 on melanoma cell lines in vitro.J Steroid Biochem Mol Biol. 2004 May;89–90(1–5):375–9.
• Pigment anomaly caused by calcipotriol in a subject with melanoma.J Eur Acad Dermatol Venereol. 2004 Jan;18(1):113–5.
• Epidemiology of cutaneous melanoma and non‑melanoma skin cancer in Schleswig‑Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer).Br J Dermatol. 2003 Dec;149(6):1200–6.
• Studies on the influence of vitamin D3 metabolites on apoptosis induction in human neoplastic cells.Acta Pol Pharm. 2003 Sep–Oct;60(5):363–6.
• Ultraviolet radiation: sun exposure, tanning beds, and vitamin D levels. What you need to know and how to decrease the risk of skin cancer. J Am Osteopath Assoc. 2003 Aug;103(8):371–5. Review.
• Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma.Dermatol Surg. 2002 Dec;28(12):1143–52. Review.
• Influence of vitamin D3 metabolites on cell proliferation and cytotoxicity of adriamycin in human normal and neoplastic cells.Toxicol In Vitro. 2002 Dec;16(6):663–7.
• Vitamin D and systemic cancer: is this relevant to malignant melanoma?Br J Dermatol. 2002 Aug;147(2):197–213. Review.
• Delay in the diagnosis of cutaneous melanoma: an analysis of 233 patients.Melanoma Res. 2002 Aug;12(4):389–94.
• A non‑calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin.Bioorg Med Chem. 2001 Sep;9(9):2365–71.
• Expression and regulation of parathyroid hormone‑related peptide in normal and malignant melanocytes.Am J Physiol Cell Physiol. 2000 Oct;279(4):C1230–8.
• Natural metabolites of 1alpha,25‑dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor.J Cell Biochem. 2000 Apr;78(1):112–20.
• Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma.Clin Cancer Res. 2000 Feb;6(2):498–504.
• Environmental factors in nonmelanoma and melanoma skin cancer.J Epidemiol. 1999 Dec;9(6 Suppl):S102–14. Review.
• Skin cancer and solar UV radiation.Eur J Cancer. 1999 Dec;35(14):2003–9. Review.
• Positive and negative interaction of 1,25‑dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis.Int J Cancer. 1999 May 5;81(3):467–70.
• Novel 19‑nor‑hexafluoride vitamin D3 analog (Ro 25‑6760) inhibits human colon cancer in vitro via apoptosis.Int J Oncol. 1999 May;14(5):979–85.
• Does the universal "signal transduction pathway of differentiation" exist? Comparison of different cell differentiation experimental models with differentiation of HL‑60 cells in response to 1,25‑dihydroxyvitamin D3Postepy Hig Med Dosw. 1999;53(2):305–13. Review in Polish.
• Differential apoptotic response of human melanoma cells to 1 alpha,25‑dihydroxyvitamin D3 and its analogues.Cell Death Differ. 1998 Nov;5(11):946–52.
• Down‑regulation of laminin‑binding integrins by 1 alpha,25‑dihydroxyvitamin D3 in human melanoma cells in vitro.Cell Adhes Commun. 1998 Mar;5(2):109–20.
• Vitamin D receptor and growth inhibition by 1,25‑dihydroxyvitamin D3 in human malignant melanoma cell lines.J Surg Res. 1996 Feb 15;61(1):127–33.
• Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Vitamins, cancer and receptors.Adv Exp Med Biol. 1995;375:1–15.
• Seasonal variation in frequency of diagnosis of cutaneous malignant melanoma.Melanoma Res. 1994 Aug;4(4):235–41.
• Beneficial effects of sun exposure on cancer mortality.Prev Med. 1993 Jan;22(1):132–40. Review.
• Rising trends in melanoma. An hypothesis concerning sunscreen effectiveness.Ann Epidemiol. 1993 Jan;3(1):103–10. Review.
• Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.Pigment Cell Res. 1992;Suppl 2:285–94.
• I alpha‑25‑dihydroxyvitamin D3 increases intracellular free calcium in murine B16 melanoma.Br J Dermatol. 1989 Jan;120(1):21–30.
• 1,25‑Dihydroxyvitamin D3 decreases expression of HLA class II molecules in a melanoma cell line.J Immunol. 1988 Jun 1;140(11):4013–8.
• Human melanoma cells: functional modulation by calciotropic hormones.J Invest Dermatol. 1988 Jun;90(6):834–40.
• Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25‑dihydroxyvitamin D3.Cancer Res. 1987 Jan 1;47(1):21–5.
• 1,25‑Dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells.Biochem Biophys Res Commun. 1986 Sep 30;139(3):1292–8.
• 1,25‑Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation.J Clin Invest. 1986 Aug;78(2):557–66.
• Effect of 1 alpha,25‑dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum‑free conditions.J Invest Dermatol. 1986 Jun;86(6):709–14.
• Biochemical significance of enhanced activity of fluorinated 1,25‑dihydroxyvitamin D3 in human cultured cell lines.Cell Biochem Funct. 1986 Apr;4(2):115–22.
• Seasonality of presentation of cutaneous melanoma, squamous cell cancer and basal cell cancer in the Oxford Region.Br J Cancer. 1985 Dec;52(6):893–900.
• Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25‑dihydroxyvitamin D3 and retinoic acid.Cancer Res. 1985 Apr;45(4):1474–8.
• Regulation of cell differentiation and tumor promotion by 1 alpha,25 dihydroxyvitamin D3.Carcinog Compr Surv. 1985;10:275–86.
• Seasonal patterns in the diagnosis of malignant melanoma of skin and eye in upstate New York.Cancer. 1984 Dec 1;54(11):2587–94.
• 1 alpha, 25‑Dihydroxyvitamin D3 specifically induces its own metabolism in a human cancer cell line.Endocrinology. 1984 Apr;114(4):1225–31.
• The synthesis of vitamin D metabolites by human melanoma cells.J Clin Endocrinol Metab. 1983 Sep;57(3):627–31.
• Inhibition of human cancer cell growth by 1,25‑dihydroxyvitamin D3 metabolites.Cancer Res. 1983 Sep;43(9):4443–7.
• 1,25‑dihydroxyvitamin D3 receptors in human epithelial cancer cell lines.Cancer Res. 1982 Mar;42(3):856–9.
• Presence of 1,25‑dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.Cancer Res. 1982 Mar;42(3):1116–9.
• 1,25‑dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture.Endocrinology. 1981 Mar;108(3):1083–6.

back to research menu